Regeneus (ASX:RGS) Presentation, FNN Investor Event, May 2019, Sydney

Company Presentations

Regeneus Limited (ASX:RGS) CEO Leo Lee presents on the company's 1H19 results, its portfolio of novel cell-based therapies, progress with its Phase 2 trial of Progenza and strategy at FNN's Investor Event.

Key points:

  • A clinical-stage regenerative medicine company
  • Portfolio of innovative cellular therapies
  • These target significant unmet medical needs with a licence-driven strategy
  • Focus on osteoarthritis and other musculoskeletal disorders
  • Focus on neuropathic pain and dermatology
  • Lead drug in knee osteoarthritis (US$5 billion addressable market)

For more, watch CEO Leo Lee present.